%0 Journal Article
%A Trautwein, Nils F
%A Mattern, Sven
%A Hinterleitner, Martina
%A Reischl, Gerald
%A Schirrmacher, Ralf
%A Steger, Volker
%A Nadalin, Silvio
%A Nikolaou, Konstantin
%A Schwenck, Johannes
%A Singer, Stephan
%A la Fougère, Christian
%T Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer.
%J Journal of nuclear medicine
%V 66
%N 8
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2025-01062
%P 1204-1209
%D 2025
%Z 2025 Aug 1;66(8):1204-1209
%X Radiolabeled somatostatin analogs (SSAs), such as [68Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [18F]SITATE presents a promising alternative, offering the advantage of a longer half-life than 68Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [18F]SITATE. Methods: This study retrospectively included 47 patients (57
%K PET (Other)
%K SSTR PET (Other)
%K [18F]SITATE (Other)
%K neuroendocrine neoplasms (Other)
%K oncology (Other)
%K radiotracer tissue kinetics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40404394
%R 10.2967/jnumed.125.269619
%U https://inrepo02.dkfz.de/record/301541